In estrogen receptor-positive (ER+) breast cancer, PAK1 hyperactivation mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors by driving epithelial-to-mesenchymal transition (EMT) and MAPK pathway activation. This evidence concerns the gene PAK1 and breast cancer.